1.14.14.25: cholesterol 24-hydroxylase
This is an abbreviated version!
For detailed information about cholesterol 24-hydroxylase, go to the full flat file.
Word Map on EC 1.14.14.25
-
1.14.14.25
-
alzheimer
-
24s-hydroxycholesterol
-
oxysterols
-
cyp27a1
-
efavirenz
-
24-hydroxylation
-
medicine
-
27-hydroxylase
-
24s-ohc
-
epsilon4
-
lathosterol
-
desmosterol
-
cholesterol-metabolizing
-
drug development
- 1.14.14.25
- alzheimer
- 24s-hydroxycholesterol
- oxysterols
- cyp27a1
- efavirenz
-
24-hydroxylation
- medicine
-
27-hydroxylase
-
24s-ohc
-
epsilon4
- lathosterol
- desmosterol
-
cholesterol-metabolizing
- drug development
Reaction
Synonyms
24S-hydroxylase, CH24H, cholesterol 24-hydroxylase, cholesterol 24-monooxygenase, cholesterol 24S hydroxylase, cholesterol 24S-hydroxylase, cholesterol hydroxylase, cholesterol-24S-hydroxylase, CYP46, CYP46A, CYP46A1, cytochrome P-450 46A1, cytochrome P450 46A1, cytochrome P450 cholesterol 24-hydroxylase, EC 1.14.13.98
ECTree
Advanced search results
Application
Application on EC 1.14.14.25 - cholesterol 24-hydroxylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
generation of imidazo[1,2-a]pyridine analogues that effectively inhibit cholesterol 24-hydroxylase (CYP46A1). They can be used for prophylactic treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease
medicine
-
CYP46A1 affects the pathophysiology of AD and provides insight into how polymorphisms in the CYP46A1 gene might influence the pathophysiology of this prevalent disease
medicine
-
genotyping of CYP46A1 gene polymorphisms (associated with the risk of Alzheimer's disease in Chinese)
medicine
-
abnormal expression of cholesterol 24S-hydroxylase in astrocytes in Alzheimer's disease, which may limit the usefulness of the plasma marker 24S-hydroxycholesterol in this specific disease
medicine
restoring CYP46A1 activity in the striatum promises a therapeutic approach in Huntington's disease
medicine
the enzyme is a potential target for Alzheimers disease as it can be activated pharmacologically by some of the marketed drugs as exemplified by efavirenz (EFV), the anti-HIV medication